A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/495 (2006.01) A61P 37/02 (2006.01)
Patent
CA 2498261
The present invention relates to compounds of the formula (I) and the pharmaceutically acceptable forms thereof; wherein X, Y, a, b, c, d, R1, R2, R3, R4 and R5 are as defined herein. Moreover, the present invention is also directed at pharmaceutical compositions comprising a compound of the formula (I) and a pharmaceutically acceptable carrier. Furthermore, the present invention is directed at methods of using the herein described compounds and compositions for treating or preventing a disorder or condition that can be treated or prevented by antagonizing the CCR1 receptor in a mammal.
L'invention porte sur des composés de la formule (I) et sur des formes pharmaceutiquement acceptables de ce dernier, X, Y, a, b, c, d, R?1¿, R?2¿, R?3¿, R?4¿ et R?5¿ étant tels que décrits ci-contre. De plus, l'invention concerne aussi des compositions pharmaceutiques contenant un composé de la formule (I) et un excipient pharmaceutiquement acceptable. En outre, l'invention se rapporte à des procédés d'utilisation des composés susmentionnés et des compositions pour le traitement ou la prévention d'un trouble ou d'une condition que l'on peut traiter ou prévenir par antagonisation du récepteur CCR1 chez un mammifère.
Blumberg Laura Cook
Brown Matthew Frank
Gaweco Anderson See
Gladue Ronald Paul
Hayward Matthew Merrill
Pfizer Products Inc.
Sim & Mcburney
LandOfFree
Use of piperazine derivatives as ccr1 antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of piperazine derivatives as ccr1 antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of piperazine derivatives as ccr1 antagonists will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1973245